The National Institute on Drug Abuse (NIDA), in collaboration with the Office of AIDS Research of the National Institutes of Health, invited national ...
06/01/1998 | Public Health Rep. 113(Suppl 1):81-89
Description:
To break the link between drug use and the human immunodeficiency virus (HIV), in 1992 the state of Connecticut rescinded a 14-year ban on pharmacy sa...
06/01/1998 | Public Health Rep. 113(Suppl 1):31-41
Description:
The purpose of this chapter is to describe the results of a randomized study (funded by the National Institute on Drug Abuse [NIDA]) comparing a peer-...
06/01/1998 | Public Health Rep. 113(Suppl 1):58-66
Description:
Community-based outreach to drug injectors is an important component of human immunodeficiency virus (HIV) prevention strategy. The purpose of this ch...
06/01/1998 | Public Health Rep. 113(Suppl 1):19-30
Description:
Over the past decade, a body of observational research has accrued about the effects of outreach-based human immunodeficiency virus (HIV) intervention...
Jun 1998 | Public Health Rep. 113(Suppl 1):160-169
Description:
This analysis describes the Outreach-Assisted Model of Partner Notification, an innovative strategy for encouraging seropositive injecting drug users ...
As the acquired immunodeficiency syndrome (AIDS) epidemic among drug users enters its third decade in the United States, it is important to consider t...
This chapter attempts to describe the factors influencing the transmission of syringe-born viruses, to review the effects of syringe exchange programs...
Since 1985, community outreach efforts to combat acquired immunodeficiency syndrome (AIDS) among injecting drug users (IDUs) in the United States have...
Jun 1998 | Public Health Rep. 113(Suppl 1):194-204
Description:
After more than 10 years of experience conducting behavioral changes interventions and with accumulated research results, several emergent principle h...
Injecting drug users (IDUs) are at high risk for infection by human immunodeficiency virus (HIV) and other blood-borne pathogens. In the United States...
Jun 1998 | Public Health Rep. 113(Suppl 1):182-188
Description:
Acquired immunodeficiency syndrome (AIDS) was formally identified among injecting drug users (IDUs) in 1981, and research on preventing human immunode...
Jun 1998 | Public Health Rep. 113(Suppl 1):189-193
Description:
Five policy advocates and practitioners provide recommendations to researchers to make research data more usable, accessible, and applicable for the f...
Jun 1998 | Public Health Rep. 113(Suppl 1):116-128
Description:
High risk injection practices are common among injecting drug users (IDUs), even following intervention efforts. Moreover, relapse to risk behaviors h...
Jun 1998 | Public Health Rep. 113(Suppl 1):129-139
Description:
Although lowering incidence rates of human immunodeficiency virus (HIV) transmission is the primary goal of needle exchange programs (NEPs), other des...
Jun 1998 | Public Health Rep. 113(Suppl 1):107-115
Description:
We undertook a study of the role of methadone maintenance in protecting injecting drug users (IDUs) from human immunodeficiency virus (HIV) infection ...
Jun 1998 | Public Health Rep. 113(Suppl 1):140-150
Description:
To review human immunodeficiency virus (HIV) risk reduction interventions among injecting drug users (IDUs) that have adopted a network approach.|The ...
This chapter attempts to describe the factors influencing the transmission of syringe-born viruses, to review the effects of syringe exchange programs...
Injecting drug users (IDUs) are at high risk for infection by human immunodeficiency virus (HIV) and other blood-borne pathogens. In the United States...
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC)
cannot attest to the accuracy of a non-federal website.
Linking to a non-federal Website does not constitute an
endorsement by CDC or any of its employees of the sponsors
or the information and products presented on the website.
You will be subject to the destination website's privacy
policy when you follow the link.
CDC is not responsible for Section 508 compliance
(accessibility) on other federal or private websites.
For more information on CDC's web notification policies, see Website Disclaimers.
[PDF-3.90 MB]
No Description
No Description
